公开(公告)号：US20240067750A1

公开(公告)日：2024-02-29

申请号：US18157312

申请日：2023-01-20

Applicant: NOVARTIS AG

Inventor： Jorg EDER ,  Stefan EWERT ,  Ulrich HASSIEPEN ,  Yasser KHDER ,  Lorenz MAYR ,  Samu MELKKO ,  Nikolaus SCHIERING

IPC: C07K16/36 ,  A61K39/395 ,  A61K45/06 ,  A61P7/02 ,  C07K16/40

CPC classification number: C07K16/36 ,  A61K39/3955 ,  A61K45/06 ,  A61P7/02 ,  C07K16/40 ,  A61K2039/505

Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20220152011A1

公开(公告)日：2022-05-19

申请号：US17589281

申请日：2022-01-31

Applicant: NOVARTIS AG

Inventor： Jorg EDER ,  Richard Alexander HARRISON ,  Boerje HARALDSSON ,  Anna Svenja WELLENSIEK SCHUBART

IPC: A61K31/454 ,  A61P13/12

Abstract: The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).